Related references
Note: Only part of the references are listed.Changes in the MALT1-A20-NF-κB expression pattern may be related to T cell dysfunction in AML
Li Shi et al.
CANCER CELL INTERNATIONAL (2013)
PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
Benjamin J. Chen et al.
CLINICAL CANCER RESEARCH (2013)
The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia
Davide Brusa et al.
HAEMATOLOGICA (2013)
Cellular immunotherapy for refractory hematological malignancies
John L. Reagan et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia
Lisa Christiansson et al.
PLOS ONE (2013)
Blockade of the PD-1 pathway enhances the efficacy of adoptive cell therapy against cancer
Weiyi Peng et al.
ONCOIMMUNOLOGY (2013)
Therapeutic advancement of chronic lymphocytic leukemia
Kang Lu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2012)
Alternative expression of TCRζ related genes in patients with chronic myeloid leukemia
Xianfeng Zha et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2012)
Tumor Immunotherapy Directed at PD-1
Antoni Ribas
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Functional differences between low- and high-affinity CD8+ T cells in the tumor environment
Rinke Bos et al.
ONCOIMMUNOLOGY (2012)
Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia
Qing Zhou et al.
BLOOD (2011)
PD-1/PD-L1 Interactions Contribute to Functional T-Cell Impairment in Patients Who Relapse with Cancer After Allogeneic Stem Cell Transplantation
Wieger J. Norde et al.
CANCER RESEARCH (2011)
Programmed Death Ligand 1 Is Expressed by Non-Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T Cells
David J. Andorsky et al.
CLINICAL CANCER RESEARCH (2011)
Restricted TRBV repertoire in CD4(+) and CD8(+) T-cell subsets from CML patients
Yangqiu Li et al.
HEMATOLOGY (2011)
Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications
Shinichiro Takahashi
JOURNAL OF HEMATOLOGY & ONCOLOGY (2011)
Graft-versus-Leukemia (GVL) against Mouse Blast-Crisis Chronic Myelogenous Leukemia (BC-CML) and Chronic-Phase Chronic Myelogenous Leukemia (CP-CML): Shared Mechanisms of T Cell Killing, but Programmed Death Ligands Render CP-CML and Not BC-CML GVL Resistant
Catherine Matte-Martone et al.
JOURNAL OF IMMUNOLOGY (2011)
Decreased level of recent thymic emigrants in CD4+ and CD8+ T cells from CML patients
Yangqiu Li et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2010)
Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression
Sabine Mumprecht et al.
BLOOD (2009)
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Loise M. Francisco et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients
T. Kozako et al.
LEUKEMIA (2009)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma
Ryo Yamamoto et al.
BLOOD (2008)
Clinical significance of B7-H1 (PD-L1) expression in human acute leukemia
Xiangli Chen et al.
CANCER BIOLOGY & THERAPY (2008)
Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies
Raanan Berger et al.
CLINICAL CANCER RESEARCH (2008)
Structures of PD-1 with its ligands: Sideways and dancing cheek to cheek
Gordon J. Freeman
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Augmented expression of programmed death-1 in both neoplastic and non-neoplastic CD4+ T-cells in adult T-cell leukemia/lymphoma
Takatoshi Shimauchi et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
PD-1 and PD-1 ligands: from discovery to clinical application
Taku Okazaki et al.
INTERNATIONAL IMMUNOLOGY (2007)
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses
Manish J. Butte et al.
IMMUNITY (2007)
IMGT Colliers de Perles and IgSF domain standardization for T cell costimulatory activatory (CD28, ICOS) and inhibitory (CTLA4, PDCD1 and BTLA) receptors
Vijay Phani Garapati et al.
DEVELOPMENTAL AND COMPARATIVE IMMUNOLOGY (2007)
Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity
LP Chen
NATURE REVIEWS IMMUNOLOGY (2004)
Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses
SC Liang et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2003)
The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice
MJI Ansari et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
PD-1 inhibits antiviral immunity at the effector phase in the liver
YH Iwai et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis
AD Salama et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Defective expression of the T-cell receptor-CD3 zeta chain in T-cell acute lymphoblastic leukaemia
GF Torelli et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues
M Ishida et al.
IMMUNOLOGY LETTERS (2002)
Share Paper
